Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s171835 ◽

2018 ◽

Vol Volume 13 ◽

pp. 2969-2984 ◽

Cited By ~ 17

Author(s):

Brian J Lipworth ◽

David J Collier ◽

Yasuhiro Gon ◽

Nanshan Zhong ◽

Koichi Nishi ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Phase Iii ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Patient Reported ◽

Metered Dose ◽

The Usa ◽

Phase Iii Study ◽

Delivery Technology ◽

Formoterol Fumarate

Download Full-text

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol

Respiratory Medicine ◽

10.1016/j.rmed.2019.08.010 ◽

2019 ◽

Vol 158 ◽

pp. 59-66 ◽

Cited By ~ 8

Author(s):

Klaus F. Rabe ◽

Fernando J. Martinez ◽

Gary T. Ferguson ◽

Chen Wang ◽

Dave Singh ◽

...

Keyword(s):

Triple Therapy ◽

Study Protocol ◽

Phase Iii ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Metered Dose ◽

Phase Iii Study ◽

Delivery Technology ◽

Severe Copd ◽

Formoterol Fumarate

Download Full-text

Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

10.1055/s-0039-3403160 ◽

2020 ◽

Author(s):

KF Rabe ◽

LM Fabbri ◽

FJ Martinez ◽

GT Ferguson ◽

E Bourne ◽

...

Keyword(s):

Seasonal Variation ◽

Phase Iii ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Post Hoc Analysis ◽

Copd Exacerbations ◽

Metered Dose ◽

Phase Iii Study ◽

Post Hoc ◽

Formoterol Fumarate

Download Full-text

Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)

10.1183/13993003.congress-2019.pa2481 ◽

2019 ◽

Author(s):

Klaus F. Rabe ◽

Leonardo M. Fabbri ◽

Fernando J. Martinez ◽

Gary T. Ferguson ◽

Eric Bourne ◽

...

Keyword(s):

Phase Iii ◽

Dose Inhaler ◽

Time Interval ◽

Metered Dose Inhaler ◽

Metered Dose ◽

Phase Iii Study ◽

Formoterol Fumarate

Download Full-text

Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1571 ◽

2019 ◽

Author(s):

K.F. Rabe ◽

L.M. Fabbri ◽

F.J. Martinez ◽

G.T. Ferguson ◽

E. Bourne ◽

...

Keyword(s):

Seasonal Variation ◽

Phase Iii ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Post Hoc Analysis ◽

Copd Exacerbations ◽

Metered Dose ◽

Phase Iii Study ◽

Post Hoc ◽

Formoterol Fumarate

Download Full-text

Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects

European Journal of Pharmaceutical Sciences ◽

10.1016/j.ejps.2020.105472 ◽

2020 ◽

Vol 153 ◽

pp. 105472

Author(s):

Samuel Israel ◽

Ashish Kumar ◽

Kiernan DeAngelis ◽

Magnus Aurivillius ◽

Paul Dorinsky ◽

...

Keyword(s):

Dose Inhaler ◽

Metered Dose Inhaler ◽

Healthy Male ◽

Pulmonary Deposition ◽

Metered Dose ◽

Male Subjects ◽

Delivery Technology ◽

Formoterol Fumarate

Download Full-text

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s171707 ◽

2018 ◽

Vol Volume 13 ◽

pp. 2673-2684 ◽

Cited By ~ 10

Author(s):

Wilfried De Backer ◽

Jan De Backer ◽

Wim Vos ◽

Ilse Verlinden ◽

Cedric Van Holsbeke ◽

...

Keyword(s):

Randomized Study ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Metered Dose ◽

Delivery Technology ◽

Formoterol Fumarate

Download Full-text

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Respiratory Research ◽

10.1186/s12931-016-0491-8 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 14

Author(s):

Colin Reisner ◽

Leonardo M. Fabbri ◽

Edward M. Kerwin ◽

Charles Fogarty ◽

Selwyn Spangenthal ◽

...

Keyword(s):

Fixed Dose ◽

Dose Inhaler ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Metered Dose Inhaler ◽

Obstructive Pulmonary Disease ◽

Metered Dose ◽

Dose Combination ◽

Delivery Technology ◽

Formoterol Fumarate

Download Full-text

12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-Suspension Delivery Technology in Patients with COPD

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3351 ◽

2019 ◽

Author(s):

G.T. Ferguson ◽

K.F. Rabe ◽

E. Bourne ◽

S. Ballal ◽

K. DeAngelis ◽

...

Keyword(s):

Lung Function ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Metered Dose ◽

Delivery Technology ◽

Function Assessment ◽

Formoterol Fumarate

Download Full-text

Long-term Effects of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) on Patient-Reported Outcomes and Health-care Utilization in African-American Patients With Asthma

CHEST Journal ◽

10.1378/chest.1117486 ◽

2011 ◽

Vol 140 (4) ◽

pp. 237A

Author(s):

Randall Brown ◽

Christopher O'Brien ◽

Ubaldo Martin ◽

Tom Uryniak ◽

Kathy Lampl

Keyword(s):

Health Care ◽

African American ◽

Patient Reported Outcomes ◽

Dose Inhaler ◽

Care Utilization ◽

Metered Dose Inhaler ◽

Long Term Effects ◽

Patient Reported ◽

Metered Dose

Download Full-text

Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study

10.1055/s-0039-3403159 ◽

2020 ◽

Author(s):

FJ Martinez ◽

GT Ferguson ◽

E Bourne ◽

S Ballal ◽

P Darken ◽

...

Keyword(s):

Lung Function ◽

Subgroup Analysis ◽

Recent History ◽

Dose Inhaler ◽

Metered Dose Inhaler ◽

Metered Dose ◽

History Of ◽

Delivery Technology ◽

Formoterol Fumarate

Download Full-text

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol

Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)

Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects

A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-Suspension Delivery Technology in Patients with COPD

Long-term Effects of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) on Patient-Reported Outcomes and Health-care Utilization in African-American Patients With Asthma

Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol